CASE STUDY | PHARMACEUTICAL PRICING STRATEGY
When Pricing Decisions Lacked Precision, We Built a Data-Driven Strategy.
THE CHALLENGE
Determining Optimal Pricing Across Multiple Indications
A clinical-stage biotech company needed to define an optimal pricing strategy for a pipeline asset being developed across multiple indications.
The asset’s clinical performance, expected positioning in treatment algorithms, and perceived value varied by indication, creating complexity in how pricing should be structured to support access and long-term value.
To maximize the asset’s potential, the company needed a strategy that accounted for these differences while optimizing long-range financial performance across the full clinical program.
THE BREAKTHROUGH
Building a Data-Driven Pricing Strategy Aligned to Market Dynamics
BGBx Consulting experts identified that pricing could not be set in isolation. It needed to reflect how value is evaluated across stakeholders and how pricing decisions impact access, utilization, and adoption across indications.
The approach integrated:
- Primary research with KOLs, high-volume prescribing physicians, and payers to assess perceived value and pricing thresholds across indications
- Quantitative survey analysis to define optimized isolation price by indication
- Development of a price elasticity model integrated into the client’s long-range plan
- Design of 15 to 20 additional pricing strategies and mechanisms to enhance value across the portfolio
THE RESULTS
Pricing Strategy Driving Long-Term Portfolio Value
The pricing strategy more than doubled the asset’s forecasted cumulative net income over the 10-year long-range plan period. This was achieved by aligning pricing to indication-specific value and market dynamics, supported by price elasticity modeling and stakeholder-informed insights across indications.
More than 2x
Forecasted Net Income
Increase over 10 years
Our Perspectives on Advertising
2026 Oncology Market Access Trends
Implications of the IRA’s Maximum Fair Price (MFP) Negotiations
340B Drug Discount Program
Let’s Plan Your Next Pricing Breakthrough
At BGBx, we design pricing strategies that align value to market dynamics across indications. We connect evidence, stakeholder expectations, and financial modeling to maximize long-term asset performance.
